



DRUG PRICES ARE RISING DRAMATICALLY!



Revlimid is primarily used to treat multiple myeloma, a form of blood cancer diagnosed in approximately **30,000 Americans each year**.

Celgene more than tripled the price of Revlimid, from \$215 per pill at launch to \$719 per pill in 2019. After acquiring Celgene, Bristol Myers Squibb further increased the price to \$763 per pill.

Surge in Drug Prices Tied to Greater Profits!



*Net price after rebates and discounts.

**Additional net revenue attributable to the price increase for 2016: \$296,747,311.87

***Additional net revenue attributable to the price increase for 2017: \$581,311,831.98